VX-440

CFTR corrector

Phase of research

Phase Two Clinical Trial

How it helps

Restore CFTR Function


General information

N/A


Synonyms

Olacaftor


Marketed as

N/A


Dietary sources

N/A

Structure not available

C29H34FN3O4S


Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
F508del/1717-1G->A
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/1898+1G->A
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/2184delA
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/2184insA
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/3120+1G->A
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/3659delC
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/621+1G->T
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/F508del
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/G542X
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/G85E
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/I507del
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/N1303K
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/Q493X
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/R1162X
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/R347P
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/R553X
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/R560T
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.
F508del/W1282X
1 0.00
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with tezacaftor and ivacaftor.

Does not treat

Mutation Number of sources Average impact factor